Combination Approaches in PD-L1–Positive Metastatic Triple Negative Breast Cancer

Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving frontline treatment landscape for triple-negative breast cancer (TNBC).   Join us as we welcomed Dr. Sherene Loi, a leading breast medical oncologist from Australia, to discuss the challenges of treating TNBC and the exciting new treatment options available. We explored the significance of PD-L1 scoring in metastatic TNBC, the implications of recent trials like ASCENT-04, and the potential of antibody-drug conjugates (ADCs) such as sacituzumab govitecan and datopotamab deruxtecan. Key topics included: The role of PD-L1 positivity in treatment decisions Insights from the ASCENT-04 trial and its findings Common side effects associated with sacituzumab and strategies for management The future of immunotherapy and ADCs in TNBC treatment Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable information and clinical pearls.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/    Don't forget to subscribe for more insightful discussions on cancer treatment! #TNBC, #PDL1positive, #ASCENT04, #Immunotherapy, #OncBrothers